Here's Why You Should Retain CONMED (CNMD) Stock for Now
https://www.zacks.com/stock/news/2210112/here-s-why-you-should-retain-conmed-cnmd-stock-for-now?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2210112
Jan 15, 2024 - CONMED (CNMD) continues to raise optimism among investors, owing to its broad product spectrum.
0
Strength Seen in Integer (ITGR): Can Its 3.8% Jump Turn into More Strength?
https://www.zacks.com/stock/news/2209378/strength-seen-in-integer-itgr-can-its-3-8-jump-turn-into-more-strength?cid=CS-ZC-FT-tale_of_the_tape|daily_price_change_3%-2209378
Jan 12, 2024 - Integer (ITGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
0
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
https://www.zacks.com/stock/news/2208303/veradigm-mdrx-medallies-partner-for-better-care-decisions?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208303
Jan 10, 2024 - Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
0
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
https://www.zacks.com/stock/news/2207546/qiagen-qgen-gains-from-new-alliances-amid-fx-headwind?cid=CS-ZC-FT-analyst_blog|zer_report_update-2207546
Jan 09, 2024 - QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
0
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
https://www.zacks.com/stock/news/2207539/senestech-s-snes-new-partnership-to-broaden-evolve-s-scope?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2207539
Jan 09, 2024 - The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
0
Here's Why Investors Should Retain Abbott (ABT) Stock Now
https://www.zacks.com/stock/news/2207160/here-s-why-investors-should-retain-abbott-abt-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2207160
Jan 08, 2024 - Investors are optimistic about Abbott (ABT) led by solid prospects in the Diagnostic business and raised guidance.
0
Here's Why You Should Retain Accuray (ARAY) Stock for Now
https://www.zacks.com/stock/news/2207061/here-s-why-you-should-retain-accuray-aray-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2207061
Jan 08, 2024 - The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
0
Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now
https://www.zacks.com/stock/news/2205758/here-s-why-you-should-retain-myriad-genetics-mygn-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205758
Jan 04, 2024 - Investors are optimistic about Myriad Genetics (MYGN) on robust testing volumes and strong solvency position.
0
Enovis (ENOV) to Strengthen Portfolio Via Its Latest Buyout
https://www.zacks.com/stock/news/2205741/enovis-enov-to-strengthen-portfolio-via-its-latest-buyout?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2205741
Jan 04, 2024 - Enovis' (ENOV) latest buyout is expected to expand its international scale with a complementary global customer base and product mix and improve efficiency with innovative manufacturing facilities.
0
Reasons to Retain Quest Diagnostics (DGX) Stock for Now
https://www.zacks.com/stock/news/2205238/reasons-to-retain-quest-diagnostics-dgx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2205238
Jan 03, 2024 - Investors are optimistic about Quest Diagnostics (DGX) on strength in base business and strategic collaborations.
0